Acute cytotoxic effects of photoimmunotherapy assessed by 18F-FDG PET

Journal of Nuclear Medicine

Volumn 54, Issue 5, 2013, Pages 770-775

  Sano, Kohei ^a   Mitsunaga, Makoto ^a   Nakajima, Takahito ^a   Choyke, Peter L ^a   Kobayashi, Hisataka ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

18F FDG; Acute cytotoxicity; Monitoring therapy; PET; Photoimmunotherapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORODEOXYGLUCOSE F 18; IR 700; PANITUMUMAB; PANITUMUMAB IR 700; PHTHALOCYANINE; TRASTUZUMAB; TRASTUZUMAB IR 700; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG UPTAKE; FEMALE; GLUCOSE TRANSPORT; HISTOPATHOLOGY; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; INFRARED RADIATION; MOUSE; NEOPLASM; NONHUMAN; PATIENT MONITORING; PHOTOIMMUNOTHERAPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE;

18F-FDG; ACUTE CYTOTOXICITY; MONITORING THERAPY; PET; PHOTOIMMUNOTHERAPY;

ANIMALS; FLUORODEOXYGLUCOSE F18; IMMUNOTHERAPY; LIGHT; MICE; NEOPLASMS; NIH 3T3 CELLS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84877105955     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.112110     Document Type: Article

References (24)

1. Waldmann TA. Immunotherapy: past, present and future. Nat Med. 2003;9:269-277. (Pubitemid 36362781)
2. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10:317-327.
3. Hambley TW, Hait WN. Is anticancer drug development heading in the right direction? Cancer Res. 2009;69:1259-1262.
4. Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL, Kobayashi H. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med. 2011;17:1685-1691.
5. Mitsunaga M, Nakajima K, Sano K, Kramer-Marek G, Choyke L, Kobayashi H. Immediate in vivo target-specific cancer cell death after near infrared photoimmunotherapy. BMC Cancer. 2012;12:345.
6. Choi H, Charnsangavej C, de Castro Faria S, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR. 2004;183:1619-1628. (Pubitemid 44210530)
7. 18F-FDG PET. J Nucl Med. 2009;50(suppl 1):97S-105S.
8. Weber WA. Assessing tumor response to therapy. J Nucl Med. 2009;50(suppl 1):1S-10S.
9. Shankar LK, Van den Abbeele A, Yap J, Benjamin R, Scheutze S, Fitzgerald TJ. Considerations for the use of imaging tools for phase II treatment trials in oncology. Clin Cancer Res. 2009;15:1891-1897.
10. 18F-FDG-PET/CT imaging as an early survival predictor in patients with primary high grade soft tissue sarcomas undergoing neoadjuvant therapy. Clin Cancer Res. 2012;18:2024-2031.
11. Warburg O, Posener K, Negelein E. Hyper metabolism of tumors [in German]. Biochem Z. 1924;152:319-344.
12. Warburg O. On the origin of cancer cells. Science. 1956;123:309-314.
13. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 2001;358:1421-1423. (Pubitemid 33055745)
14. 18F- FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med. 2004;45:17-21.
15. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1996.
16. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol. 2001;38:17-23. (Pubitemid 32194591)
17. Mitsunaga M, Nakajima T, Sano K, Choyke PL, Kobayashi H. Near-infrared theranostic photoimmunotherapy (PIT): repeated exposure of light enhances the effect of immunoconjugate. Bioconjug Chem. 2012;23:604-609.
18. 11C-choline. J Nucl Med. 2011;52:81-89.
19. 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med. 2009;50:1820-1827.
20. Kimura H, Lee C, Hayashi K, et al. UV light killing efficacy of fluorescent protein-expressing cancer cells in vitro and in vivo. J Cell Biochem. 2010;110:1439-1446.
21. Tsai MH, Aki R, Amoh Y, et al. GFP-fluorescence-guided UVC irradiation inhibits melanoma growth and angiogenesis in nude mice. Anticancer Res. 2010;30:3291-3294.
22. 18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. J Nucl Med. 2004;45:1754-1758.
23. Su H, Bodenstein C, Dumont RA, et al. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 2006;12:5659-5667. (Pubitemid 44629592)
24. Holdsworth CH, Badawi RD, Manola JB, et al. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR. 2007;189:W324-330.